{
    "nctId": "NCT00178802",
    "briefTitle": "Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers",
    "officialTitle": "Phase II Study of Mild Whole Body Hyperthermia Combined With 5-Fluorouracil/Interferon-a/Liposomal Doxorubicin in Patients With Advanced Malignancy",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasms, Endometrial Neoplasms, Cervix Neoplasms, Ovarian Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "Tumor response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Resistant breast, endometrial, cervix, or ovarian cancer\n* No active metastasis to the brain\n* No more than 8 previous regimes of Doxil\n* Successful completion of preliminary function tests\n* Good ECOG score\n\nExclusion Criteria:\n\n* Active metastasis to the brain\n* 8 or more previous cycles of Doxil\n* Poor completion of preliminary function tests\n* Poor ECOG score",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}